"id:ID","id","name","uuid","text","label","description","instanceType"
"758","Objective_1","OBJ1","33102947-5df5-4db3-969c-e1f75e5b16d2","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Main objective","OBJECTIVE"
"759","Objective_2","OBJ2","6c65e2a2-8b42-432c-955f-802089cfb4e4","To document the safety profile of the xanomeline TTS.","","Safety","OBJECTIVE"
"760","Objective_3","OBJ3","2f679f3e-07f1-414d-951d-6427dfde5ae4","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Behaviour","OBJECTIVE"
